 BURLINGAME, Calif., March 04, 2021 GLOBE NEWSWIRE -- ALX Oncology Holdings Inc. ALX Oncology Nasdaq: ALXO, a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, and Tallac Therapeutics, Inc. Tallac, a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced a collaboration to jointly develop, manufacture, and commercialize a novel class of cancer immunotherapeutics. Under the terms of the agreement, ALX Oncology and Tallac will share equally in the cost of research and development and any profits or losses incurred. 